Ad hoc-Mitteilungen

Lonza to Establish Large-Scale, Commercial Drug Product Fill & Finish Facility in Stein (CH)

| Aufrufe: 210

Lonza Group AG / Key word(s): Expansion Lonza to Establish Large-Scale, Commercial Drug Product Fill & Finish Facility in Stein (CH) 01-Jul-2022 / 07:01 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement.


Ad hoc announcement pursuant to Art. 53 LR

 
  • Lonza to build a new large-scale, commercial drug product fill and finish facility to support customers across the entire product life cycle
  • Lonza will invest approximately CHF 500 million in the facility, fulfilling its strategic commitment to establish a commercial fill and finish offering that completes its full value chain
 
Basel, Switzerland, 1 July 2022 – Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, today announced plans to construct a large-scale commercial drug product fill and finish facility in Stein (CH).

The investment will enable the company to provide customers with a complete and integrated end-to-end solution that includes commercial drug product manufacturing for large-scale market supply. The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026.

About Lonza Lonza is a preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our unparalleled breadth of offerings enables our customers to commercialize their discoveries and innovations in the healthcare industry.

Lonza Contact Details

Additional Information and Disclaimer Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual. Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.


End of ad hoc announcement
Language: English
Company: Lonza Group AG
Münchensteinerstrasse 38
4052 Basel
Switzerland
Phone: +4161 316 81 11
Internet: www.lonza.com
ISIN: CH0013841017
Valor: 1384101
Listed: SIX Swiss Exchange
EQS News ID: 1388413
 
End of Announcement EQS News Service

1388413  01-Jul-2022 CET/CEST

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
Kurs:
Lonza Group
-3,50%
584,80 $  


Schließen

Lukrative Investment-Idee

Die nächste große Chance! Noch völlig unbekannt, aber unverzichtbar & unersetzlich! HELIUM bald in aller Munde
weiterlesen»